End effector including an implantable arrangement

• US 10,258,330 B2
• Filed: 06/22/2015
• Issued: 04/16/2019
• Est. Priority Date: 09/30/2010
• Status: Active Grant

• Current Assignee: Cilag Gmbh International (Johnson & Johnson)
• Original Assignee: Ethicon, LLC (Johnson & Johnson)
• Inventors: Shelton, IV, Frederick E., Schmid, Katherine J., Scheib, Charles J., Aronhalt, Taylor W., Swayze, Jeffrey S., Contiliano, Joseph H., Yang, Chunlin, Henderson, Cortney E., Aldridge, Jeffrey L.
• Primary Examiner(s): Lopez, Michelle
• Application Number:
  US14/746,387
• Publication Number:
  US 20150282810A1
• Time in Patent Office: 1,394 Days
• Field of Search: 2271751, 606151
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61B 17/064 Surgical staples, i.e. penetrating the tissue
• CPC Class Codes: A61B 17/0643 with separate closing member, e.g. for interlocking with staple
• CPC Class Codes: A61B 17/0644 penetrating the tissue, deformable to closed position
• CPC Class Codes: A61B 17/068 Surgical staplers , e.g. containing multiple staples or clampsstaplers containing only one staple A61B17/10; magazines or containers for staples A61B17/105; for performing anastomosis A61B17/115; staplers in general B25C5/00
• CPC Class Codes: A61B 17/072 for applying a row of staples in a single action , e.g. the staples being applied simultaneously
• CPC Class Codes: A61B 17/07207 the staples being applied sequentially
• CPC Class Codes: A61B 17/07292 Reinforcements for staple line, e.g. pledgets
• CPC Class Codes: A61B 17/105 Wound clamp magazines for packaging sharps A61B50/3001
• CPC Class Codes: A61B 17/1155 Circular staplers comprising a plurality of staples
• CPC Class Codes: A61B 17/30 Surgical pincettes without pivotal connectionsfor holding suture needles or materials A61B17/0483; wound clamps A61B17/08 ; hand-held gripping tools without pivotal connections in general B25B9/02
• CPC Class Codes: A61B 2017/00004 (bio)absorbable, (bio)resorbable, resorptive for implantable prostheses A61F2210/0004
• CPC Class Codes: A61B 2017/00526 Methods of manufacturing
• CPC Class Codes: A61B 2017/0053 Loading magazines or sutures into applying tools
• CPC Class Codes: A61B 2017/00893 pharmaceutically effective
• CPC Class Codes: A61B 2017/00991 Telescopic means
• CPC Class Codes: A61B 2017/07228 Arrangement of the staples
• CPC Class Codes: A61B 2017/07235 containing different staples, e.g. staples of different shapes, sizes or materials
• CPC Class Codes: A61B 2017/07242 achieving different staple heights during the same shot, e.g. using an anvil anvil having different heights or staples of different sizes
• CPC Class Codes: A61B 2017/07257 characterised by its anvil
• CPC Class Codes: A61B 2017/07264 : characterised by its staple forming cavities, e.g. geometry or material
• CPC Class Codes: A61B 2017/07271 : characterised by its cartridge
• CPC Class Codes: A61B 2017/07278 : characterised by its sled or its staple holder
• CPC Class Codes: A61B 2017/2916 : pins in guiding slots
• CPC Class Codes: A61B 2017/2923 : Toothed members, e.g. rack and pinion
• CPC Class Codes: A61B 2017/2937 : with flexible part

Abstract

In various embodiments, an end effector comprising a first jaw, a second jaw, an implantable arrangement, first cavities, and second cavities is disclosed. At least one of the first and second jaws is movable to compress tissue between the first jaw and second jaws. The implantable arrangement comprises a first layer and a second layer. The first layer and the second layer comprise a polymeric composition. The first cavities are defined in the first layer and interconnectedly form a permeable first layer. The first cavities releasably retain a first therapeutic agent configured to induce a first biological response in the tissue. The second cavities are defined in the second layer and interconnectedly form a permeable second layer. The second cavities releasably retain a second therapeutic agent configured to induce a second biological response in the tissue. The first therapeutic agent and the second therapeutic agent are different.

Claims

1. An end effector, comprising:

a first jaw;

a second jaw, wherein at least one of said first jaw and said second jaw is movable to compress tissue between said first jaw and said second jaw;

an implantable arrangement comprising a first layer and a second layer, wherein said first layer and said second layer comprise a polymeric composition;

a plurality of first cavities defined in said first layer, wherein said first cavities interconnectedly form a permeable first layer, wherein said first cavities releasably retain a first therapeutic agent, and wherein said first therapeutic agent is configured to induce a first biological response in the tissue; and

a plurality of second cavities defined in said second layer, wherein said second cavities interconnectedly form a permeable second layer, wherein said second cavities releasably retain a second therapeutic agent, and wherein said second therapeutic agent is configured to induce a second biological response in the tissue, wherein said first therapeutic agent and said second therapeutic agent are different, and wherein said first cavities and said second cavities are separate and distinct from one another.

2. The end effector of claim 1, wherein said implantable arrangement further comprises a third layer, and wherein said third layer envelops said first layer and said second layer.

3. The end effector of claim 2, wherein said third layer is configured to prevent the release of said first therapeutic agent and said second therapeutic agent from said implantable arrangement until said third layer is incised.

4. The end effector of claim 1, wherein said interconnected first cavities form a first network of channel paths for said first therapeutic agent when released, and wherein said interconnected second cavities form a second network of channel paths for said second therapeutic agent when released.

5. The end effector of claim 4, wherein said first therapeutic agent comprises a hemostatic agent, and wherein said first biological response comprises reducing bleeding of the tissue.

6. The end effector of claim 4, wherein said first therapeutic agent comprises an anti-inflammatory agent, and wherein said first biological response comprises reducing inflammation of the tissue.

7. The end effector of claim 4, wherein said second therapeutic agent comprises an antimicrobial agent, and wherein said second biological response comprises reducing infection of the tissue.

8. The end effector of claim 4, wherein said second therapeutic agent comprises an anticancer agent, and wherein said second biological response comprises inhibiting cancer growth of the tissue.

9. The end effector of claim 1, wherein said polymeric composition comprises a biocompatible foam.

10. The end effector of claim 9, wherein said biocompatible foam comprises a pore morphology arranged to induce tissue in-growth.

11. An end effector, comprising:

a first jaw;

a second jaw, wherein at least one of said first jaw and said second jaw is movable to compress tissue between said first jaw and said second jaw;

an implantable compensator comprising a plurality of layers defining a structural matrix, wherein each of said layers comprises a fibrous weave; and

a first cavity defined within a first fibrous weave of a first layer of said layers, wherein said first cavity is structured to releasably retain more than one therapeutic agent, and wherein said more than one therapeutic agent are configured to induce at least one biological response in the tissue, and wherein said more than one therapeutic agent are different from one another.

12. The end effector of claim 11, wherein said more than one therapeutic agent comprises at least one hemostatic agent, and wherein the at least one biological response comprises reducing bleeding of the tissue.

13. The end effector of claim 11, wherein said more than one therapeutic agent comprises at least one anti-inflammatory agent, and wherein the at least one biological response comprises reducing inflammation of the tissue.

14. The end effector of claim 11, wherein said more than one therapeutic agent comprises at least one antimicrobial agent, and wherein the at least one biological response comprises reducing infection of the tissue.

15. An end effector, comprising:

a first jaw including a cartridge comprising a plurality of staples;

a second jaw including an anvil comprising a plurality of staple forming pockets, wherein at least one of said first jaw and said second jaw is movable to compress tissue between said cartridge and said anvil;

a compensator comprising a matrix including a plurality of fibrous layers, wherein said compensator is implantable against the tissue when said staples are ejected from said cartridge to penetrate the tissue and said compensator;

a cutting member configured to incise the tissue and said compensator along a cutting line when said compensator is implanted; and

a cavity defined within a said fibrous layer, wherein said cavity is structured to openly retain at least one therapeutic agent, wherein said cavity is aligned with one of a said staple forming pocket to release said at least one therapeutic agent to treat the penetrated tissue or said cutting line to release said at least one therapeutic agent to treat the incised tissue, and wherein said at least one therapeutic agent is configured to induce at least one biological response in the tissue.

16. The end effector of claim 15, wherein said at least one therapeutic agent comprises a hemostatic agent, and wherein the at least one biological response comprises reducing bleeding of the tissue.

17. The end effector of claim 15, wherein said at least one therapeutic agent comprises an anti-inflammatory agent, and wherein the at least one biological response comprises reducing inflammation of the tissue.

18. The end effector of claim 15, wherein said at least one therapeutic agent comprises an antimicrobial agent, and wherein the at least one biological response comprises reducing infection of the tissue.

19. The end effector of claim 15, wherein each of said plurality of fibrous layers comprises a plurality of cavities, and wherein said layers and said cavities of said matrix are structured to induce tissue and cellular in-growth.

20. The end effector of claim 19, wherein each of said plurality of fibrous layers comprises fibers configured to induce extracellular matrix secretion.

21. The end effector of claim 15, wherein said matrix further includes a biocompatible foam comprising a pore morphology arranged to induce tissue in-growth.